Pathological fractures and lytic bone lesion of the femoral neck associated with ?2-microglobulin amyloid deposition in long-term dialysis patients

1991 ◽  
Vol 110 (2) ◽  
pp. 93-97 ◽  
Author(s):  
G. F. W. Scheumann ◽  
M. Holch ◽  
M. L. Nerlich ◽  
A. Brandis ◽  
H. Ostertag ◽  
...  
Neurosurgery ◽  
2012 ◽  
Vol 71 (4) ◽  
pp. E901-E904 ◽  
Author(s):  
Karen J. Fritchie ◽  
Mitchel D. Bauman ◽  
Quentin J. Durward

Abstract BACKGROUND AND IMPORTANCE: Myoepithelioma of bone is a rare osseous tumor thought to be related to myoepithelial lesions found at other anatomic sites such as the salivary gland and skin. These tumors are composed of varying proportions of epithelial and myoepithelial cells and exhibit a spectrum of biologic behavior ranging from benign to malignant. We present the first reported case of myoepithelioma of the skull. CLINICAL PRESENTATION: A 20-year-old white woman presented with a persistent right parieto-occipital skull nodule, relating its presence to a fall on the site 2 years previously. The nodule had become painful in the past 2 months. Her past medical history and workup were otherwise unremarkable. The initial biopsy was inconclusive for diagnosis. The lytic bone lesion was subsequently resected, and histopathological examination showed a proliferation of epithelioid cells in a myxochondroid background. Fluorescence in situ hybridization studies revealed a rearrangement of the EWSR1 locus. The morphologic and molecular findings were consistent with the diagnosis of myoepithelioma of bone. CONCLUSION: Six months after surgery, the patient is doing well with no evidence of recurrence. This case illustrates the clinical presentation, histopathology, and molecular findings of a myoepithelioma of the skull with successful surgical treatment. Because myoepitheliomas with benign morphological appearance may rarely act aggressively, long-term clinical follow-up is warranted.


1990 ◽  
Vol 23 (2) ◽  
pp. 195-198
Author(s):  
Seishi Inoue ◽  
Masayuki Azuma ◽  
Toshiaki Hirabayashi ◽  
Oshi Inagaki ◽  
Hidetaro Mori ◽  
...  

2021 ◽  
Vol 24 (2) ◽  
pp. 4-47
Author(s):  
Zh. E. Belaya ◽  
K. Yu. Belova ◽  
E. V. Biryukova ◽  
I. I. Dedov ◽  
L. K. Dzeranova ◽  
...  

Due to continuous aging of population and increase in the number of elderly people, osteoporosis became socially significant disease leading to disability, increasing mortality and thereby putting an additional burden on the public healthcare system.Screening to identify groups with a high probability of fracture is recommended using the FRAX® Tool for all postmenopausal women and men over 50 years old (А1). In the presense of major pathological fractures (hip, spine, multiple fractures) it is recommended to diagnose osteoporosis and prescribe treatment regardless of the results of spine and hip double X-ray absorptiometry (DXA) or FRAX® (B2).It is recommended to evaluate C-terminal telopeptide when prescribing antiresorptive therapy and procollagen type 1 N-terminal propeptide (P1NP) when prescribing anabolic therapy to patients receiving osteoporosis treatment at baseline and 3 months after the start of therapy in order to assess the effectiveness of treatment early and adherence to the therapy (А2). It is recommended to diagnose osteoporosis and prescribe treatment to patients with high individual 10-year probability of major pathological fractures (FRAX®) regardless of the results of spine and hip DXA (В3).It is recommended to diagnose osteoporosis and prescribe treatment with a decrease in BMD, measured by DXA, by 2.5 or more T-score standard deviations in femoral neck, and/or in total hip, and/or in lumbar vertebrae, in postmenopausal women and men over 50 years old (А2).It is recommended to prescribe bisphosphonates, denosumab or teriparatide to prevent pathological fractures and increase BMD in patients with postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis (А2). When the clinical effect of therapy in osteoporotic patients without pathological fractures is achieved (BMD T-score > -2.0 SD in femoral neck and absence of new fractures), it is recommended to interrupt bisphosphonates therapy for 1-2 years with subsequent follow-up (B2). In patients with vertebral fractures, hip fractures or multiple fractures, it is recommended to continue ceaseless long-term treatment of osteoporosis (В3).All drugs for the treatment of osteoporosis are recommended to be prescribed in combination with calcium and cholecalciferol (А2). In order to reduce the risk of recurrent fractures by prescribing osteoporosis therapy timely and maintaining long-term follow-up of patients over 50 years old with pathological fractures, it is recommended to create Fracture Liaison Services (В2).


2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii546-iii547
Author(s):  
Marios Theodoridis ◽  
Stylianos Panagoutsos ◽  
Eleni Triantafyllidou ◽  
Pelagia Kriki ◽  
Konstantia Kantartzi ◽  
...  

Circulation ◽  
2013 ◽  
Vol 128 (4) ◽  
pp. 344-351 ◽  
Author(s):  
Maxwell D. Leither ◽  
Gautam R. Shroff ◽  
Shu Ding ◽  
David T. Gilbertson ◽  
Charles A. Herzog

Nephrology ◽  
2016 ◽  
Vol 22 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Sam Stuart ◽  
David Stott ◽  
Antony Goode ◽  
Charlotte J Cash ◽  
Andrew Davenport

Injury ◽  
2005 ◽  
Vol 36 (1) ◽  
pp. 123-130 ◽  
Author(s):  
Emre Togrul ◽  
Huseyin Bayram ◽  
Mahir Gulsen ◽  
Aydıner Kalacı ◽  
Serdar Özbarlas

Sign in / Sign up

Export Citation Format

Share Document